TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients wit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Del Bianco, Paola, Stagni, Camilla, Giunco, Silvia, Fabozzi, Alessio, Elefanti, Lisa, Pellegrini, Stefania, Vecchiato, Antonella, Pigozzo, Jacopo, Zamuner, Carolina, De Rossi, Anita, De Nicolo, Arcangela, Menin, Chiara
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226422/
https://ncbi.nlm.nih.gov/pubmed/32290374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040946
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky